Diaz-Feijoo B, et al. - Researchers appraised their experience with sentinel lymph node (SLN) biopsy in patients with early-stage cervical cancer, and reported factors that determine the rate of false negatives. At the Vall d’Hebron Hospital (Barcelona, Spain), 128 patients were diagnosed with early-stage cervical cancer (FIGO-2009 stages 1A2, IB1, and IIA1) between September 2000 and October 2016. They identified The combined SLN detection rate (99-technecium and a blue dye) of 98.4%, bilateral in 76% of the patients. Findings support the feasibility of SLN mapping and biopsy in early-stage cervical cancer to detect patients with initial metastases with high sensitivity. Certain groups of patients, such as those with tumors ≤ 2 cm and no lymphovascular space invasion, had lower risk of false negatives.